Data and Analytics
How Customized Copay Analytics Help Brands Build Market Share
Data needs vary from brand to brand. It’s critical for pharma brands to employ customized copay analytics strategies for their patient access programs.
5 Strategies for Achieving Transparency in Your Pharmacy Contract
How can you build more transparency in your pharmacy contract? We lay out five critical strategies to ensure you have control and oversight over your program.
Webinar - Pharmacy Benefits 101: What Employers Need to Know About PBMs and Drug Spend
In this Truveris webinar, we join Mployer Advisor to tackle pharmacy benefits 101. What should payers know about PBMs as they plan for 2023?
3 Patient Access Strategies Setting Innovative Brands Apart
The gross-to-net bubble is inflating. What patient access strategies are leading brands using to combat this trend?
7 Indicators that Your Drug is a Strong Candidate for Accumulator and Maximizer Programs
How should pharma companies plan for if their drugs will be included in accumulator or maximizer programs? Use our interactive checklist.
Webinar - Transparency in Pharmacy: Innovative Strategies to Drive Outcomes for Self-Funded Plans
How can you inject more transparency into your pharmacy plan? Watch the recording of our webinar.
The Truveris Pharmacy Benefits Glossary of Terms
Truveris’ Pharmacy Benefits Glossary of Terms provides important definitions and context to help navigate the pharmacy benefits landscape.
Webinar - HR Leaders' Perspective: Priorities and Challenges for Employee Benefits in 2022 and Beyond
Watch Truveris’ exclusive Human Resources round table, originally recorded on June 8th, 2022.
What Self-Funded Plans Should Know About Copay Assistance Programs
Plan sponsors are looking for new ways to contain specialty costs. How should they evaluate new copay assistance strategies?
What Pharma Should Know About How Employers are Approaching Accumulators and Maximizers
Truveris covers exactly how leading employer groups and their brokers are implementing copay maximizers and accumulators.
How to Manage High-Cost Specialty Drug Spend for Self-Funded Plans
As pharmacy costs increase, what are strategies plan sponsors can take to control specialty pharmacy spend?
3 Ways to Avoid Drug Launch Mistakes
With so much importance placed on the launch of a new drug, how should pharma brands ensure a successful launch?
Webinar - Copay Maximizers and Alternative Funding: What Self-Funded Plans Should Know
How are copay maximizers and alternative funding impacting plans – and members? Watch our on-demand webinar to learn more.
Truveris Launches the First Member-Centric Patient Engagement Solution, oneRx™
Truveris announces the launch of oneRx, the only drug price transparency solution that helps members navigate their pharmacy benefits.
4 Reasons Why Member Engagement Fuels a Pharmacy Benefits Plan
After you procure a strong PBM contract, make sure your members are engaging with the plan productively.
Case Studies: How Truveris' Pharmacy Benefits Procurement Solutions Create Savings
See how Truveris has helped employers of all sizes procure their pharmacy benefits.
The Three Pillars of Pharmacy Benefits Strategy
By framing your pharmacy benefits strategy around these three pillars, you’ll construct a more cost-effective, accessible pharmacy program.
How are COVID-19 Variants Impacting Pharmaceutical Brands?
With Delta and Omicron, the COVID-19 pandemic carries on. How are these variants impacting pharma brands?
3 Strategies for Pharma Brands to Navigate the January Claims Drop
Many brands experience a drop in claims during January. What strategies successfully drive adherence during the beginning of the year?
How Member-Centricity Drives Effective Pharmacy Strategy
What is member-centricity? Why should plan sponsors and brokers strive to reimagine their pharmacy program with members in mind?
The Impact of COVID-19 on Brand Prescribing and Claims
Read Truveris’ data report on the impact of COVID-19 on pharma, specifically prescribing and claims numbers for branded drugs.
Gene Therapy and Cell Therapy: Key Payer Considerations
Many gene therapy products are soon to be released to the market. What do payers need to know about these highly-expensive specialty drugs?
Podcast - The Future of the PBM Landscape
What is the future of the PBM landscape? Listen to Truveris CEO, Nanette Oddo, opine on the shifts she’s seeing in the pharmacy ecosystem.
7 Critical Terms to Help Save Money on Your PBM Contracts
Get up to speed on all the industry-speak and confusing jargon that surrounds the work of PBMs.
Is Your Patient Abandonment Rate Really What You Think it is?
Your entire access strategy hinges on your patient abandonment rate. Is your patient abandonment rate calculated correctly?